Skip to search formSkip to main contentSkip to account menu

ISIS 5132

Known as: ISIS 5132/CGP69846A, ISIS-5132, ISIS5132 
A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA. ISIS 5132 has been shown to specifically suppress… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antineoplastic AgentsAntisense OligonucleotidesEnzyme InhibitorsThionucleotides

Narrower (1)

CGP 69846A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Safety of nanoparticles based on albumin-polymer conjugates as a carrier of nucleotides for pancreatic cancer therapy.
Gene therapy through systemic administration is expected to offer significant therapeutic potential against intractable cancers… 
2015
2015
An Oligonucleotide Transfection Vector Based on HSA and PDMAEMA Conjugation: Effect of Polymer Molecular Weight on Cell Proliferation and on Multicellular Tumor Spheroids.
A novel gene transfection vector was fabricated based on the conjugation of human serum albumin (HSA) and maleimide end… 
2009
2009
Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer
Background: A phase I trial was performed to evaluate the administration of carboplatin/paclitaxel in combination with ISIS-5132… 
Highly Cited
2002
Highly Cited
2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
PURPOSE Protein kinase C (PKC)-alpha and Raf-1 are important elements of proliferative signal transduction pathways in both… 
Highly Cited
2002
Highly Cited
2002
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
BACKGROUND Because treatment of metastatic colon cancer is noncurative, new treatments are needed. This trial evaluated the… 
Highly Cited
2001
Highly Cited
2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Raf-1 is a serine/threonine kinase that functions as a critical effector of Ras-mediated signal transduction via the mitogen… 
Highly Cited
2000
Highly Cited
2000
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic… 
Highly Cited
1999
Highly Cited
1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
PURPOSE Raf-1 is a protein kinase that plays a broad role in oncogenic signaling and acts as a downstream effector of Ras in the… 
Highly Cited
1999
Highly Cited
1999
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
Abnormally regulated signaling through proliferative signal transduction pathways characterizes many of the common solid tumors… 
1998
1998
Preconcentration and separation of antisense oligonucleotides by on‐column isotachophoresis and capillary electrophoresis in polymer‐filled capillaries
Small, single‐stranded, chemically modified oligonucleotides, complementary to a specific gene section, commonly referred to as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License